Vivaldi Biosciences
Latest round
- Series A
Last raised
- Jan 2009
Total raised
- $21M
Investors
- 4
About Vivaldi Biosciences
Vivaldi Biosciences, Inc.Vivaldi Biosciences, Inc. specializes in vaccine development for viral respiratory diseases, notably employing its proprietary Delta NS1 technology platform. The company is headquartered in New York, US. Bill Wick serves as the CEO.Vivaldi Biosciences specializes in the development of innovative vaccines targeting viral respiratory diseases, with a focus on their proprietary Delta NS1 technology platform. Delta NS1 serves as a replication-deficient vaccine vector derived from a genetically modified, attenuated influenza virus strain. This platform enables the creation of broadly protective, self-adjuvanting vaccines that can be administered via nasal spray, with particular applications in combating influenza and COVID-19. The vaccines are designed to rapidly induce interferon, a key immune signaling protein, which enhances protective immunity against circulating viruses.Vivaldi Biosciences operates within a framework that emphasizes collaborative partnerships and clinical trials to advance its vaccine offerings. Transactions primarily involve agreements for clinical research and development that may lead to licensing opportunities for their flagship Delta NS1-based vaccines, including the DeltaFLU universal influenza vaccine and the Delta-19 COVID-19 and universal influenza combination vaccine. The company aims to design and launch new products targeting respiratory diseases, with an emphasis on expanding into North America and Europe by 2025. Their strategy includes advancing the DeltaFLU and Delta-19 vaccines through clinical trials to secure regulatory approvals and subsequent commercialization.
Who invested in Vivaldi Biosciences
4 investors across 2 rounds
See all investors in Vivaldi Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Vivaldi Biosciences
Who invested in Vivaldi Biosciences?
Vivaldi Biosciences has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vivaldi Biosciences raised?
Vivaldi Biosciences has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Vivaldi Biosciences last raise money?
Vivaldi Biosciences's most recent round on record is a Series A, in Jan 2009.
What does Vivaldi Biosciences do?
Vivaldi Biosciences is a pharmaceuticals company.
Where is Vivaldi Biosciences headquartered?
Vivaldi Biosciences is headquartered in New York, US.
Which VCs invest in companies like Vivaldi Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Vivaldi Biosciences's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Vivaldi Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.